13F filing recap · Q3 2025
What did Hillman Capital Management buy in Q3 2025?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every Hillman account, including accounts that belong to no fund below.
Stock value
$171.85M
Positions
53
Estimated turnover
29.9%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Hillman Capital Management opened new positions in Fiserv, UnitedHealth Group, West Pharmaceutical Services, United Parcel Service, and Thermo Fisher Scientific, while exiting AT&T and Advanced Micro Devices entirely. The firm substantially reduced its stake in Warner Bros. Discovery and significantly added to Campbell’s. Other notable moves included trimming ASML, Estee Lauder, CVS Health, Microsoft, DuPont, Nike, Taiwan Semiconductor, T. Rowe Price, Nucor, US Bancorp, Hershey, General Electric, and Alphabet, while adding to Baxter International and CarMax.